No Data
No Data
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA For Treatment Of Triple Negative Breast Cancer
Express News | Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA for Treatment of Triple Negative Breast Cancer (Tnbc)
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Express News | Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality
Express News | Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
No Data
No Data
AhmadFH : Thanks Jag
71580478 : love it, thanks! what do you think about SHIM?
JMK47 : thanks for all your effort
101628821 : Is it going to melt or continue to rise today?
101821671 : Do you have any opinions on the stock symbol SOAR?
View more comments...